Moving the goal posts in prostate cancer trials

doi:10.1016/S1470-2045(15)70071-9

Comment

. 2015 Mar;16(3):247-9.

doi: 10.1016/S1470-2045(15)70071-9. Epub 2015 Feb 18.

Moving the goal posts in prostate cancer trials

Ravi A Madan¹, James L Gulley²

Affiliations

¹ National Cancer Institute, National Institutes of Health, Center Drive, Bethesda, MD 20892, USA.
² National Cancer Institute, National Institutes of Health, Center Drive, Bethesda, MD 20892, USA. Electronic address: gulleyj@mail.nih.gov.

PMID: 25701172
PMCID: PMC6632068
DOI: 10.1016/S1470-2045(15)70071-9

Comment

Moving the goal posts in prostate cancer trials

Ravi A Madan et al. Lancet Oncol. 2015 Mar.

. 2015 Mar;16(3):247-9.

doi: 10.1016/S1470-2045(15)70071-9. Epub 2015 Feb 18.

Authors

Ravi A Madan¹, James L Gulley²

Affiliations

¹ National Cancer Institute, National Institutes of Health, Center Drive, Bethesda, MD 20892, USA.
² National Cancer Institute, National Institutes of Health, Center Drive, Bethesda, MD 20892, USA. Electronic address: gulleyj@mail.nih.gov.

PMID: 25701172
PMCID: PMC6632068
DOI: 10.1016/S1470-2045(15)70071-9

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare that we have no competing interests.

Comment on

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Saad F, et al. Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701170 Clinical Trial.

Cited by

Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?
Modena A, Massari F, Ciccarese C, Brunelli M, Santoni M, Montironi R, Martignoni G, Tortora G. Modena A, et al. Target Oncol. 2016 Aug;11(4):431-46. doi: 10.1007/s11523-015-0412-7. Target Oncol. 2016. PMID: 26846650 Review.

References

1. Saad F, Fizazi K, Jinga V, et al., for the ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 2015; published online Feb 18. 10.1016/S1470-2045(15)70027-6. - DOI - PubMed
1. Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015; 10.1200/JCO.2014.56.5119. - DOI - PMC - PubMed
1. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014; 32: 3436–48. - PMC - PubMed
1. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028–38. - PMC - PubMed
1. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–33. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Grants and funding

Z01 BC010945/ImNIH/Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources

[1] Saad F, Fizazi K, Jinga V, et al., for the ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 2015; published online Feb 18. 10.1016/S1470-2045(15)70027-6. - DOI - PubMed

[2] Saad F, Fizazi K, Jinga V, et al., for the ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 2015; published online Feb 18. 10.1016/S1470-2045(15)70027-6. - DOI - PubMed

[3] Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015; 10.1200/JCO.2014.56.5119. - DOI - PMC - PubMed

[4] Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015; 10.1200/JCO.2014.56.5119. - DOI - PMC - PubMed

[5] Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014; 32: 3436–48. - PMC - PubMed

[6] Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014; 32: 3436–48. - PMC - PubMed

[7] Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028–38. - PMC - PubMed

[8] Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028–38. - PMC - PubMed

[9] Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–33. - PMC - PubMed

[10] Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–33. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Moving the goal posts in prostate cancer trials

Affiliations

Moving the goal posts in prostate cancer trials

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources